Drug delivery company, pSivida Corp. (NASDAQ: PSDV)(ASX: PVA)(FF: PV3), together with its licensing and development partner, Alimera Sciences, have today reported the interim six-month safety and efficacy results from the first human pharmacokinetici (PK) study of Medidur? FA, which will be marketed under the trade name Iluvien?, if approved by the U.S. Food and Drug Administration.
More...